Utilization, cost trends, and member cost-share for self-injectable multiple sclerosis drugs - Pharmacy and medical benefit spending from 2004 through 2007

Journal of Managed Care Pharmacy

Volumn 13, Issue 9, 2007, Pages 799-806

  Kunze, April M ^a   Gunderson, Brent W ^a   Gleason, Patrick P ^a   Heaton, Alan H ^b   Johnson, Steven V ^c  

^a Prime Therapeutics   (United States)

^b Blue Cross Blue Shield of Minnesota   (United States)

^c Clinical Consultative Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; NATALIZUMAB; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; PEPTIDE; RECOMBINANT INTERFERON;

ARTICLE; COMMUNITY CARE; CONTROLLED STUDY; COST UTILITY ANALYSIS; DRUG COST; DRUG MARKETING; DRUG UTILIZATION; GEOGRAPHIC DISTRIBUTION; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; MULTIPLE SCLEROSIS; PHARMACEUTICAL CARE; PHARMACY BENEFIT MANAGER; PROSPECTIVE PRICING; REIMBURSEMENT; SELF INJECTION; UNITED STATES; COST; DRUG SELF ADMINISTRATION; ECONOMIC ASPECT; ECONOMICS; FEE; INTRAVENOUS DRUG ADMINISTRATION; STATISTICS;

ANTIBODIES, MONOCLONAL; COST SHARING; DEDUCTIBLES AND COINSURANCE; DRUG COSTS; DRUG UTILIZATION; FEES, PHARMACEUTICAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLATION, ECONOMIC; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; INTERFERON TYPE I, RECOMBINANT; MITOXANTRONE; MULTIPLE SCLEROSIS; PEPTIDES; SELF ADMINISTRATION; UNITED STATES;

EID: 38349127878     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2007.13.9.799     Document Type: Article

References (18)

1. National Multiple Sclerosis Society. What is multiple sclerosis? August 17, 2007. Available at: www.nationalmssociety.org/site/ PageServer?pagename=HOM_LIB_brochures_what_is_ms. Accessed August 21, 2007.
2. Rizvi SA, Agius MA. Current approved options for treating patients with multiple sclerosis. Neurology. 2004;63(12):S8-S14.
3. Miller J. The importance of early diagnosis of multiple sclerosis. J Manag Care Pharm. 2004;10(3):S4-S9. Available at: www.amcp.org/data/ jmcp/June04Supplement1.pdf. Accessed October 11, 2007.
4. National Multiple Sclerosis Society. The disease-modifying drugs. November 2006. Available at: www.nationalmssociety.org/docs/HOM/ brochures/DiseaseModifyingDrugs.pdf. Accessed August 21, 2007.
5. National Multiple Sclerosis Society. Expert opinion paper. Changing therapy in relapsing multiple sclerosis: considerations and recommendations of a task force of the National Multiple Sclerosis Society. 2004. Available at: www.nationalmssociety.org/docs/HOM/ Exp_ChangTherapy.pdf. Accessed August 21, 2007.
6. Goodin DS, Frohman EM, Garmany GP, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58:169-78.
7. Rossman H. Neutralizing antibodies to multiple sclerosis treatments. J Manag Care Pharm. 2004;10(3):S12-S17. Available at: www.amcp.org/data/jmcp/June04Supplement1.pdf. Accessed October 11, 2007.
8. De Jager P, Hafler D. New therapeutic approaches for multiple sclerosis. Annual Review of Medicine. 2007,58:417-32.
9. Noronha A. Neutralizing antibodies to interferon. Neurology. 2007; 68(S4):S16-S22.
10. Prescott J, Factor S, Pill M, Levi G. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm. 2007;13(1):44-52. Available at: www.amcp.org/data/jmcp/44-52.pdf. Accessed on October 17, 2007.
11. AARP. Trends in manufacturer prices of brand-name prescription drugs used by older Americans - 2006 year-end update. Available at: http://assets.aarp.org/rgcenter/health/dd154ℝugprices.pdf. Accessed October 16, 2007.
12. U.S. Congressional Budget Office. Prescription drug pricing in the private sector. January 2007. Available at: www.cbo.gov/ftpdocs/77xx/ doc7715/01-03-PrescriptionDrug.pdf. Accessed October 16, 2007.
13. Biogen Idec, Inc. Avonex (interferon beta-1a) prescribing information. November 2006. Available at: www.avonex.com/msavProject/ avonex.portal/_baseurl/threeColLayout/SCSRepository/en_US/avonex/includes/footer / prescribe_info_med_guide.xml. Accessed October 22, 2007.
14. Berlix Laboratories and Bayer Healthcare Pharmaceuticals. Betaseron (interferon beta-1b) prescribing information. September 2007. Available at: http://berlex.bayerhealthcare.com/html/products/pi/Betaseron_PI.pdf. Accessed October 22, 2007.
15. Teva Neuroscience. Copaxone (glatiramer acetate) prescribing information. May 2007. Available at: www.copaxone.com/pdf/ PrescribingInformation.pdf. Accessed October 22, 2007.
16. Serono, Inc. and Pfizer. Rebif (interferon beta-1a) prescribing information. September 2005. Available at: www.mslifelines.com/_assets/ pdf/Rebif_PI.pdf. Accessed October 22, 2007.
17. Serono, Inc. Novantrone (mitoxantrone) prescribing information. September 2006. Available at: www.novantrone.com/assets/pdf/ novantrone_prescribing_info.pdf. Accessed October 22, 2007.
18. Biogen Idec and Elan Pharmaceuticals. Tysabri (natalizumab) prescribing information. June 2007. Available at: www.tysabri.com/tysbProject/ tysb.portal/_baseurl/twoColLayout/SCSRepository/en_US/tysb/home/ product-information/index.html. Accessed October 22, 2007.